BridgeBio Pharma, Inc. (BBIO) NASDAQ
66.13
-3.53(-5.07%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
66.13
-3.53(-5.07%)
Currency In USD
| Previous Close | 69.66 |
| Open | 68.7 |
| Day High | 69.19 |
| Day Low | 66.05 |
| 52-Week High | 84.94 |
| 52-Week Low | 31.77 |
| Volume | 2.68M |
| Average Volume | 2.54M |
| Market Cap | 12.95B |
| PE | -17.68 |
| EPS | -3.74 |
| Moving Average 50 Days | 71.34 |
| Moving Average 200 Days | 65.46 |
| Change | -3.53 |
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
GlobeNewswire Inc.
Mar 11, 2026 6:00 PM GMT
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early separation from placebo observed
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 04, 2026 12:30 PM GMT
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data fro
BridgeBio to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its manag